EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment. Through two complementary technology platforms that each activate and mobilize a different half of the immune system, innate (non-specific) and adaptive (specific) immunity, the company is developing drug candidates that are specifically toxic to tumor cells, not normal cells. EpicentRx's lead program, RRx-001, has been tested in several clinical trials, including an ongoing Phase 3 study in small cell lung cancer. It is among a portfolio of small molecule compounds that favorably alter the tumor microenvironment and activate tumor associated macrophages (TAMs) of the innate immune response. The company is also advancing multiple programs through its smart virus platform, including personalized cancer vaccines that have been shown to eradicate tumors and prevent them from returning.
EpicentRx Address
11099 North Torrey Pines Road La Jolla, CA United States
(confidential, clinical stage bio-ventures / young public companies)Independent Consultant for Corporate/Business Development & Venture Investments